Biotest AG | Balance Sheet

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
204
234
174
84
23
62
Total Accounts Receivable
123
188
187
181
151
197
Inventories
227
246
219
171
147
208
Other Current Assets
5
9
8
31
129
28
Total Current Assets
560
677
587
467
450
495
Net Property, Plant & Equipment
255
282
317
415
477
513
Total Investments and Advances
2
2
4
11
9
2
Long-Term Note Receivable
3
7
1
1
6
7
Intangible Assets
46
47
41
21
11
16
Other Assets
3
4
5
5
6
-
Total Assets
887
1,048
982
952
999
1,057
ST Debt & Current Portion LT Debt
5
6
9
16
120
Accounts Payable
51
56
53
63
65
Income Tax Payable
10
9
4
4
3
Other Current Liabilities
58
59
59
64
63
Total Current Liabilities
124
129
126
146
251
Long-Term Debt
226
326
336
330
287
Provision for Risks & Charges
65
84
79
92
89
Deferred Taxes
11
2
1
10
17
Other Liabilities
3
3
2
2
1
Total Liabilities
426
568
570
592
651
Common Equity (Total)
461
480
412
361
348
Total Shareholders' Equity
461
480
412
361
348
Total Equity
461
480
412
361
348
Liabilities & Shareholders' Equity
887
1,048
982
952
999
Accumulated Minority Interest
-
-
-
-
-

About Biotest

View Profile
Address
Landsteinerstrasse 5
Dreieich Hessen 63303
Germany
Employees -
Website http://www.biotest.de
Updated 07/08/2019
Biotest AG engages in the development and distribution of biological and biotechnological pharmaceutical products. It focuses in the field of clinical immunology, haematology, and intensive care medicine. The company operates through the following segment: Therapy, Plasma & Services, and Other.